Download PDF
CC BY 4.0 · Thromb Haemost 2018; 118(06): 959-978
DOI: 10.1055/s-0038-1648251
Review Article
Schattauer GmbH Stuttgart

Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence

Nina Buchtele
1   Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Michael Schwameis
2   Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria
,
James C. Gilbert
3   Band Therapeutics, LLC, Boston, Massachusetts, United States
,
Christian Schörgenhofer
1   Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Bernd Jilma
1   Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
› Author Affiliations Funding This study was funded by the Austrian Science Fund FWF_F 5404-B21 (Special Research Program, Cellular Mediators Linking Inflammation and Thrombosis).
Further Information

Publication History

29 November 2017

21 March 2018

Publication Date:
30 May 2018 (online)

   Permissions and Reprints

Abstract

Despite great efforts in stroke research, disability and recurrence rates in ischaemic stroke remain unacceptably high. To address this issue, one potential target for novel therapeutics is the glycoprotein von Willebrand factor (vWF), which increases in thrombogenicity especially under high shear rates as it bridges between vascular sub-endothelial collagen and platelets. The rationale for vWF as a potential target in stroke comes from four bodies of evidence. (1) Animal models which recapitulate the pathogenesis of stroke and validate the concept of targeting vWF for stroke prevention and the use of the vWF cleavage enzyme ADAMTS13 in acute stroke treatment. (2) Extensive epidemiologic data establishing the prognostic role of vWF in the clinical setting showing that high vWF levels are associated with an increased risk of first stroke, stroke recurrence or stroke-associated mortality. As such, vWF levels may be a suitable marker for further risk stratification to potentially fine-tune current risk prediction models which are mainly based on clinical and imaging data. (3) Genetic studies showing an association between vWF levels and stroke risk on genomic levels. Finally, (4) studies of patients with primary disorders of excess or deficiency of function in the vWF axis (e.g. thrombotic thrombocytopenic purpura and von Willebrand disease, respectively) which demonstrate the crucial role of vWF in atherothrombosis. Therapeutic inhibition of VWF by novel agents appears particularly promising for secondary prevention of stroke recurrence in specific sub-groups of patients such as those suffering from large artery atherosclerosis, as designated according to the TOAST classification.

Keywords

stroke prevention - von Willebrand factor - high shear rates - individualized treatment

Supplementary Material

 

  • References

  • 1 Lozano R, Naghavi M, Foreman K. , et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2095-2128
    CrossrefPubMedGoogle Scholar
  • 2 Benjamin EJ, Blaha MJ, Chiuve SE. , et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 update: a report from the American Heart Association. Circulation 2017; 135 (10) e146-e603
    CrossrefPubMedGoogle Scholar
  • 3 Tsai CF, Thomas B, Sudlow CL. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 2013; 81 (03) 264-272
    CrossrefPubMedGoogle Scholar
  • 4 Heuschmann PU, Di Carlo A, Bejot Y. , et al; European Registers of Stroke (EROS) Investigators. Incidence of stroke in Europe at the beginning of the 21st century. Stroke 2009; 40 (05) 1557-1563
    CrossrefPubMedGoogle Scholar
  • 5 Feigin VL, Forouzanfar MH, Krishnamurthi R. , et al; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383 (9913): 245-254
    CrossrefPubMedGoogle Scholar
  • 6 Mozaffarian D, Benjamin EJ, Go AS. , et al; Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive summary: Heart Disease and Stroke Statistics--2016 update: a report from the American Heart Association. Circulation 2016; 133 (04) 447-454
    CrossrefPubMedGoogle Scholar
  • 7 Di Carlo A. Human and economic burden of stroke. Age Ageing 2009; 38 (01) 4-5
    PubMedGoogle Scholar
  • 8 Adams Jr HP, Effron MB, Torner J. , et al; AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008; 39 (01) 87-99
    CrossrefPubMedGoogle Scholar
  • 9 Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev 2014; (03) CD005208
    PubMedGoogle Scholar
  • 10 Montalescot G, Wiviott SD, Braunwald E. , et al; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373 (9665): 723-731
    CrossrefPubMedGoogle Scholar
  • 11 Morrow DA, Alberts MJ, Mohr JP. , et al; Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Investigators. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 2013; 44 (03) 691-698
    CrossrefPubMedGoogle Scholar
  • 12 Denorme F, De Meyer SF. The VWF-GPIb axis in ischaemic stroke: lessons from animal models. Thromb Haemost 2016; 116 (04) 597-604
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Adams Jr HP, Bendixen BH, Kappelle LJ. , et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24 (01) 35-41
    CrossrefPubMedGoogle Scholar
  • 14 Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31 (05) 1062-1068
    CrossrefPubMedGoogle Scholar
  • 15 Koppelman SJ, van Hoeij M, Vink T. , et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87 (06) 2292-2300
    PubMedGoogle Scholar
  • 16 Hannah MJ, Williams R, Kaur J, Hewlett LJ, Cutler DF. Biogenesis of Weibel-Palade bodies. Semin Cell Dev Biol 2002; 13 (04) 313-324
    CrossrefPubMedGoogle Scholar
  • 17 Schoergenhofer C, Matzneller P, Mußbacher M. , et al. Colistin dampens fibrinolysis and endothelial activation during endotoxaemia. A randomised, double blind trial. Thromb Haemost 2017; 117 (09) 1714-1721
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Jilma B, Pernerstorfer T, Dirnberger E. , et al. Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen. J Lab Clin Med 1998; 131 (02) 151-156
    CrossrefPubMedGoogle Scholar
  • 19 Siller-Matula JM, Miller I, Gemeiner M. , et al. Continuous thrombin infusion leads to a bleeding phenotype in sheep. Thromb Res 2012; 130 (02) 226-236
    CrossrefPubMedGoogle Scholar
  • 20 Derhaschnig U, Pachinger C, Schweeger-Exeli I, Marsik C, Jilma B. Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia. Thromb Haemost 2003; 90 (06) 1054-1060
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Reiter RA, Mayr F, Blazicek H. , et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102 (13) 4594-4599
    CrossrefPubMedGoogle Scholar
  • 22 Wagner DD, Saffaripour S, Bonfanti R. , et al. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell 1991; 64 (02) 403-413
    CrossrefPubMedGoogle Scholar
  • 23 Sing CE, Alexander-Katz A. Elongational flow induces the unfolding of von Willebrand factor at physiological flow rates. Biophys J 2010; 98 (09) L35-L37
    CrossrefPubMedGoogle Scholar
  • 24 Marx I, Christophe OD, Lenting PJ. , et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood 2008; 112 (03) 603-609
    CrossrefPubMedGoogle Scholar
  • 25 Petri B, Broermann A, Li H. , et al. von Willebrand factor promotes leukocyte extravasation. Blood 2010; 116 (22) 4712-4719
    CrossrefPubMedGoogle Scholar
  • 26 De Meyer GR, Hoylaerts MF, Kockx MM, Yamamoto H, Herman AG, Bult H. Intimal deposition of functional von Willebrand factor in atherogenesis. Arterioscler Thromb Vasc Biol 1999; 19 (10) 2524-2534
    CrossrefPubMedGoogle Scholar
  • 27 Trillo AA, Prichard RW. Early endothelial changes in experimental primate atherosclerosis. Lab Invest 1979; 41 (04) 294-302
    PubMedGoogle Scholar
  • 28 Möller K, Adolph O, Grünow J. , et al. Mechanism and functional impact of CD40 ligand-induced von Willebrand factor release from endothelial cells. Thromb Haemost 2015; 113 (05) 1095-1108
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Nguyen TC, Liu A, Liu L. , et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92 (01) 121-124
    CrossrefPubMedGoogle Scholar
  • 30 Methia N, André P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001; 98 (05) 1424-1428
    CrossrefPubMedGoogle Scholar
  • 31 van Galen KP, Tuinenburg A, Smeets EM, Schutgens RE. Von Willebrand factor deficiency and atherosclerosis. Blood Rev 2012; 26 (05) 189-196
    CrossrefPubMedGoogle Scholar
  • 32 Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32 (05) 1104-1115
    CrossrefPubMedGoogle Scholar
  • 33 Bongers TN, de Maat MP, van Goor ML. , et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37 (11) 2672-2677
    CrossrefPubMedGoogle Scholar
  • 34 Folsom AR, Rosamond WD, Shahar E. , et al; The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999; 100 (07) 736-742
    CrossrefPubMedGoogle Scholar
  • 35 Williams SR, Hsu FC, Keene KL. , et al; GARNET (The Genomics and Randomized Trials Network) Collaborative Research Group. Genetic drivers of von Willebrand factor levels in an ischemic stroke population and association with risk for recurrent stroke. Stroke 2017; 48 (06) 1444-1450
    CrossrefPubMedGoogle Scholar
  • 36 Menih M, Križmarić M, Hojs Fabjan T. Clinical role of von Willebrand factor in acute ischemic stroke. Wien Klin Wochenschr 2017; 129 (13-14): 491-496
    CrossrefPubMedGoogle Scholar
  • 37 Kraft P, Drechsler C, Gunreben I. , et al. Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. PLoS One 2014; 9 (06) e99851
    CrossrefPubMedGoogle Scholar
  • 38 Samai A, Monlezun D, Shaban A. , et al. Von Willebrand factor drives the association between elevated factor VIII and poor outcomes in patients with ischemic stroke. Stroke 2014; 45 (09) 2789-2791
    CrossrefPubMedGoogle Scholar
  • 39 Bath PM, Blann A, Smith N, Butterworth RJ. Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 1998; 9 (3-4): 155-159
    CrossrefPubMedGoogle Scholar
  • 40 Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke 2007; 38 (06) 1873-1880
    CrossrefPubMedGoogle Scholar
  • 41 Favaloro EJ, Pasalic L, Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology 2016; 48 (04) 303-318
    CrossrefPubMedGoogle Scholar
  • 42 Eikenboom J, Federici AB, Dirven RJ. , et al; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood 2013; 121 (12) 2336-2339
    CrossrefPubMedGoogle Scholar
  • 43 Kleinschnitz C, De Meyer SF, Schwarz T. , et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009; 113 (15) 3600-3603
    CrossrefPubMedGoogle Scholar
  • 44 Zhao BQ, Chauhan AK, Canault M. , et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114 (15) 3329-3334
    CrossrefPubMedGoogle Scholar
  • 45 Sanders YV, Eikenboom J, de Wee EM. , et al; WiN Study Group. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 2013; 11 (05) 845-854
    CrossrefPubMedGoogle Scholar
  • 46 Peyvandi F, Scully M, Kremer Hovinga JA. , et al; TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374 (06) 511-522
    CrossrefPubMedGoogle Scholar
  • 47 Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost 1997; 77 (06) 1104-1108
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Qizilbash N, Duffy S, Prentice CR, Boothby M, Warlow C. Von Willebrand factor and risk of ischemic stroke. Neurology 1997; 49 (06) 1552-1556
    CrossrefPubMedGoogle Scholar
  • 49 Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost 2011; 9 (02) 275-281
    CrossrefPubMedGoogle Scholar
  • 50 van Schie MC, DE Maat MP, Dippel DW. , et al. von Willebrand factor propeptide and the occurrence of a first ischemic stroke. J Thromb Haemost 2010; 8 (06) 1424-1426
    CrossrefPubMedGoogle Scholar
  • 51 McCabe DJ, Murphy SJ, Starke R. , et al. Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. J Neurol Sci 2015; 348 (1-2): 35-40
    CrossrefPubMedGoogle Scholar
  • 52 Tobin WO, Kinsella JA, Kavanagh GF. , et al. Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes. J Neurol Sci 2017; 375: 404-410
    CrossrefPubMedGoogle Scholar
  • 53 Andersson HM, Siegerink B, Luken BM. , et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 2012; 119 (06) 1555-1560
    CrossrefPubMedGoogle Scholar
  • 54 Sonneveld MA, de Maat MP, Portegies ML. , et al. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood 2015; 126 (25) 2739-2746
    CrossrefPubMedGoogle Scholar
  • 55 Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17 (11) 3321-3325
    CrossrefPubMedGoogle Scholar
  • 56 Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115 (16) 2119-2127
    CrossrefPubMedGoogle Scholar
  • 57 Bevan S, Traylor M, Adib-Samii P. , et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke 2012; 43 (12) 3161-3167
    CrossrefPubMedGoogle Scholar
  • 58 Traylor M, Farrall M, Holliday EG. , et al; Australian Stroke Genetics Collaborative, Wellcome Trust Case Control Consortium 2 (WTCCC2); International Stroke Genetics Consortium. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 2012; 11 (11) 951-962
    CrossrefPubMedGoogle Scholar
  • 59 Malik R, Traylor M, Pulit SL. , et al; ISGC Analysis Group; METASTROKE collaboration; Wellcome Trust Case Control Consortium 2 (WTCCC2); NINDS Stroke Genetics Network (SiGN). Low-frequency and common genetic variation in ischemic stroke: the METASTROKE collaboration. Neurology 2016; 86 (13) 1217-1226
    CrossrefPubMedGoogle Scholar
  • 60 Auer PL, Nalls M, Meschia JF. , et al; National Heart, Lung, and Blood Institute Exome Sequencing Project. Rare and coding region genetic variants associated with risk of ischemic stroke: the NHLBI Exome Sequence Project. JAMA Neurol 2015; 72 (07) 781-788
    CrossrefPubMedGoogle Scholar
  • 61 Network NSG. ; NINDS Stroke Genetics Network (SiGN); International Stroke Genetics Consortium (ISGC). Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. Lancet Neurol 2016; 15 (02) 174-184
    CrossrefPubMedGoogle Scholar
  • 62 Dichgans M, Malik R, König IR. , et al; METASTROKE Consortium; CARDIoGRAM Consortium; C4D Consortium; International Stroke Genetics Consortium. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke 2014; 45 (01) 24-36
    CrossrefPubMedGoogle Scholar
  • 63 Van Schie MC, Wieberdink RG, Koudstaal PJ. , et al. Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study. J Thromb Haemost 2012; 10 (04) 550-556
    PubMedGoogle Scholar
  • 64 Fernández-Cadenas I, Del Río-Espínola A, Giralt D. , et al. IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke 2012; 43 (10) 2659-2665
    CrossrefPubMedGoogle Scholar
  • 65 de Lange M, Snieder H, Ariëns RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet 2001; 357 (9250): 101-105
    CrossrefPubMedGoogle Scholar
  • 66 Smith NL, Chen MH, Dehghan A. , et al; Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121 (12) 1382-1392
    CrossrefPubMedGoogle Scholar
  • 67 Huffman JE, de Vries PS, Morrison AC. , et al. Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. Blood 2015; 126 (11) e19-e29
    CrossrefPubMedGoogle Scholar
  • 68 van Loon J, Dehghan A, Weihong T. , et al. Genome-wide association studies identify genetic loci for low von Willebrand factor levels. Eur J Hum Genet 2016; 24 (07) 1035-1040
    CrossrefPubMedGoogle Scholar
  • 69 Antoni G, Oudot-Mellakh T, Dimitromanolakis A. , et al. Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. BMC Med Genet 2011; 12: 102
    PubMedGoogle Scholar
  • 70 van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost 2011; 9 (05) 899-908
    CrossrefPubMedGoogle Scholar
  • 71 Gallinaro L, Cattini MG, Sztukowska M. , et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111 (07) 3540-3545
    CrossrefPubMedGoogle Scholar
  • 72 Millar CM, Brown SA. Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease. Blood Rev 2006; 20 (02) 83-92
    CrossrefPubMedGoogle Scholar
  • 73 Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J 2007; 5: 14
    CrossrefPubMedGoogle Scholar
  • 74 Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. Transfusion 2006; 46 (10) 1836-1844
    CrossrefPubMedGoogle Scholar
  • 75 Ozel AB, McGee B, Siemieniak D. , et al. Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance. J Thromb Haemost 2016; 14 (09) 1888-1898
    CrossrefPubMedGoogle Scholar
  • 76 Desch KC, Ozel AB, Siemieniak D. , et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci U S A 2013; 110 (02) 588-593
    CrossrefPubMedGoogle Scholar
  • 77 Souto JC, Almasy L, Soria JM. , et al. Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project. Thromb Haemost 2003; 89 (03) 468-474
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 1999; 93 (12) 4277-4283
    CrossrefPubMedGoogle Scholar
  • 79 van Schie MC, de Maat MP, Isaacs A. , et al. Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood 2011; 117 (04) 1393-1399
    CrossrefPubMedGoogle Scholar
  • 80 van Loon JE, Kavousi M, Leebeek FW. , et al. von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population. J Thromb Haemost 2012; 10 (07) 1262-1269
    CrossrefPubMedGoogle Scholar
  • 81 Campos M, Sun W, Yu F. , et al. Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood 2011; 117 (19) 5224-5230
    CrossrefPubMedGoogle Scholar
  • 82 Suadicani P, Hein HO, Gyntelberg F. Airborne occupational exposure, ABO phenotype and risk of ischaemic heart disease in the Copenhagen Male Study. J Cardiovasc Risk 2002; 9 (04) 191-198
    PubMedGoogle Scholar
  • 83 Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330 (15) 1041-1046
    CrossrefPubMedGoogle Scholar
  • 84 Williams FM, Carter AM, Hysi PG. , et al; EuroCLOT Investigators; Wellcome Trust Case Control Consortium 2; MOnica Risk, Genetics, Archiving and Monograph; MetaStroke; International Stroke Genetics Consortium. Ischemic stroke is associated with the ABO locus: the EuroCLOT study. Ann Neurol 2013; 73 (01) 16-31
    CrossrefPubMedGoogle Scholar
  • 85 Ay H, Gungor L, Arsava EM. , et al. A score to predict early risk of recurrence after ischemic stroke. Neurology 2010; 74 (02) 128-135
    CrossrefPubMedGoogle Scholar
  • 86 Arsava EM, Kim GM, Oliveira-Filho J. , et al. Prediction of early recurrence after acute ischemic stroke. JAMA Neurol 2016; 73 (04) 396-401
    CrossrefPubMedGoogle Scholar
  • 87 Sonneveld MA, van Dijk AC, van den Herik EG. , et al. Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis 2013; 230 (02) 210-215
    PubMedGoogle Scholar
  • 88 Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley Jr TH, Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke 2006; 37 (10) 2493-2498
    CrossrefPubMedGoogle Scholar
  • 89 Penz SM, Reininger AJ, Toth O, Deckmyn H, Brandl R, Siess W. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost 2007; 97 (03) 435-443
    Article in Thieme ConnectPubMedGoogle Scholar
  • 90 Hobl EL, Stimpfl T, Ebner J. , et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63 (07) 630-635
    CrossrefPubMedGoogle Scholar
  • 91 Spiel AO, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula JM, Jilma B. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial. Clin Sci (Lond) 2012; 123 (10) 591-600
    CrossrefPubMedGoogle Scholar
  • 92 Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. Am Heart J 2004; 147 (04) E17
    PubMedGoogle Scholar
  • 93 Tobin WO, Kinsella JA, Kavanagh GF. , et al. Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke. J Neurol 2014; 261 (07) 1405-1412
    CrossrefPubMedGoogle Scholar
  • 94 Nilsson TK, Spence JD, Nilsson PM, Eliasson M, Jansson JH, Boman K. Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study. J Cardiovasc Risk 2002; 9 (04) 215-221
    PubMedGoogle Scholar
  • 95 National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 (24) 1581-1587
    CrossrefPubMedGoogle Scholar
  • 96 Hacke W, Kaste M, Bluhmki E. , et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 (13) 1317-1329
    CrossrefPubMedGoogle Scholar
  • 97 Wardlaw JM, Murray V, Berge E. , et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379 (9834): 2364-2372
    CrossrefPubMedGoogle Scholar
  • 98 Powers WJ, Derdeyn CP, Biller J. , et al; American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46 (10) 3020-3035
    CrossrefPubMedGoogle Scholar
  • 99 Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008; 39 (03) 924-928
    CrossrefPubMedGoogle Scholar
  • 100 Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011; 42 (07) 1952-1955
    CrossrefPubMedGoogle Scholar
  • 101 Wang Y, Liao X, Zhao X. , et al; China National Stroke Registry Investigators. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke 2011; 42 (06) 1658-1664
    CrossrefPubMedGoogle Scholar
  • 102 Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56 (08) 1015-1020
    CrossrefPubMedGoogle Scholar
  • 103 Cocho D, Belvís R, Martí-Fàbregas J. , et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005; 64 (04) 719-720
    CrossrefPubMedGoogle Scholar
  • 104 O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999; 33 (01) 9-14
    CrossrefPubMedGoogle Scholar
  • 105 Nogueira RG, Jadhav AP, Haussen DC. , et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018; 378 (01) 11-21
    CrossrefPubMedGoogle Scholar
  • 106 Vivien D. Can the benefits of rtPA treatment for stroke be improved?. Rev Neurol (Paris) 2017; 173 (09) 566-571
    CrossrefPubMedGoogle Scholar
  • 107 Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012; 43 (11) 2904-2909
    CrossrefPubMedGoogle Scholar
  • 108 Montagne A, Hébert M, Jullienne A. , et al. Memantine improves safety of thrombolysis for stroke. Stroke 2012; 43 (10) 2774-2781
    CrossrefPubMedGoogle Scholar
  • 109 Yeo LL, Paliwal P, Teoh HL. , et al. Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke. JAMA Neurol 2013; 70 (03) 353-358
    CrossrefPubMedGoogle Scholar
  • 110 Molina CA, Montaner J, Arenillas JF, Ribo M, Rubiera M, Alvarez-Sabín J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004; 35 (02) 486-490
    CrossrefPubMedGoogle Scholar
  • 111 Goyal M, Menon BK, van Zwam WH. , et al; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016; 387 (10029): 1723-1731
    CrossrefPubMedGoogle Scholar
  • 112 Singh B, Parsaik AK, Prokop LJ, Mittal MK. Endovascular therapy for acute ischemic stroke: a systematic review and meta-analysis. Mayo Clin Proc 2013; 88 (10) 1056-1065
    CrossrefPubMedGoogle Scholar
  • 113 Sheth KN, Smith EE, Grau-Sepulveda MV, Kleindorfer D, Fonarow GC, Schwamm LH. Drip and ship thrombolytic therapy for acute ischemic stroke: use, temporal trends, and outcomes. Stroke 2015; 46 (03) 732-739
    CrossrefPubMedGoogle Scholar
  • 114 Zhao W, Che R, Shang S. , et al. Low-dose tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular thrombectomy. Stroke 2017; 48 (12) 3289-3294
    CrossrefPubMedGoogle Scholar
  • 115 O'Donnell MJ, Chin SL, Rangarajan S. , et al; INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; 388 (10046): 761-775
    CrossrefPubMedGoogle Scholar
  • 116 Kernan WN, Ovbiagele B, Black HR. , et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (07) 2160-2236
    CrossrefPubMedGoogle Scholar
  • 117 Kamal AK, Naqvi I, Husain MR, Khealani BA. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011; (01) CD008076
    PubMedGoogle Scholar
  • 118 Li X, Zhou G, Zhou X, Zhou S. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. J Neurol Sci 2013; 332 (1-2): 92-96
    CrossrefPubMedGoogle Scholar
  • 119 Committee CS. ; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329-1339
    CrossrefPubMedGoogle Scholar
  • 120 Aldandashi S, Noor R, Wang CX, Uddin G, Shuaib A. Combination treatment with dipyridamole, aspirin, and tPA in an embolic model of stroke in rats. Exp Neurol 2007; 205 (02) 563-568
    CrossrefPubMedGoogle Scholar
  • 121 Lee JH, Park SY, Lee WS, Hong KW. Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. Neurol Res 2005; 27 (05) 483-492
    CrossrefPubMedGoogle Scholar
  • 122 Sacco RL, Diener HC, Yusuf S. , et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359 (12) 1238-1251
    CrossrefPubMedGoogle Scholar
  • 123 Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388 (10042): 365-375
    CrossrefPubMedGoogle Scholar
  • 124 Bath PM, Cotton D, Martin RH. , et al; PRoFESS Study Group. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke 2010; 41 (04) 732-738
    CrossrefPubMedGoogle Scholar
  • 125 Zhang Q, Wang C, Zheng M. , et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Cerebrovasc Dis 2015; 39 (01) 13-22
    CrossrefPubMedGoogle Scholar
  • 126 Diener HC, Bogousslavsky J, Brass LM. , et al; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364 (9431): 331-337
    CrossrefPubMedGoogle Scholar
  • 127 Hilkens NA, Li L, Rothwell PM, Algra A, Greving JP. External validation of risk scores for major bleeding in a population-based cohort of transient ischemic attack and ischemic stroke patients. Stroke 2018; 49 (03) 601-606
    CrossrefPubMedGoogle Scholar
  • 128 Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71 (05) 1366-1374
    PubMedGoogle Scholar
  • 129 Rosafio F, Lelli N, Mimmi S. , et al. Platelet function testing in patients with acute ischemic stroke: an observational study. J Stroke Cerebrovasc Dis 2017; 26 (08) 1864-1873
    CrossrefPubMedGoogle Scholar
  • 130 Kunicki TJ, Williams SA, Nugent DJ. , et al. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009; 101 (01) 123-133
    Article in Thieme ConnectPubMedGoogle Scholar
  • 131 Wang Y, Zhao X, Lin J. , et al; CHANCE investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016; 316 (01) 70-78
    CrossrefPubMedGoogle Scholar
  • 132 Pan Y, Chen W, Xu Y. , et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation 2017; 135 (01) 21-33
    CrossrefPubMedGoogle Scholar
  • 133 Lin Y, Wang A, Li J. , et al; CHANCE Investigators. Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke 2017; 48 (04) 998-1004
    CrossrefPubMedGoogle Scholar
  • 134 Li X, Ling L, Li C, Ma Q. Efficacy and safety of desmoteplase in acute ischemic stroke patients: a systematic review and meta-analysis. Medicine (Baltimore) 2017; 96 (18) e6667
    CrossrefPubMedGoogle Scholar
  • 135 Le Behot A, Gauberti M, Martinez De Lizarrondo S. , et al. GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood 2014; 123 (21) 3354-3363
    CrossrefPubMedGoogle Scholar
  • 136 Momi S, Tantucci M, Van Roy M, Ulrichts H, Ricci G, Gresele P. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood 2013; 121 (25) 5088-5097
    CrossrefPubMedGoogle Scholar
  • 137 Denorme F, Langhauser F, Desender L. , et al. ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. Blood 2016; 127 (19) 2337-2345
    CrossrefPubMedGoogle Scholar
  • 138 Fan M, Xu H, Wang L. , et al. Tissue plasminogen activator neurotoxicity is neutralized by recombinant ADAMTS 13. Sci Rep 2016; 6: 25971
    CrossrefPubMedGoogle Scholar
  • 139 Gilbert JC, DeFeo-Fraulini T, Hutabarat RM. , et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116 (23) 2678-2686
    CrossrefPubMedGoogle Scholar
  • 140 Knöbl P, Jilma B, Gilbert JC, Hutabarat RM, Wagner PG, Jilma-Stohlawetz P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 2009; 49 (10) 2181-2185
    CrossrefPubMedGoogle Scholar
  • 141 Peyvandi F, Scully M, Kremer Hovinga JA. , et al; TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374 (06) 511-522
    CrossrefPubMedGoogle Scholar
  • 142 Cataland SR, Peyvandi F, Mannucci PM. , et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol 2012; 87 (04) 430-432
    CrossrefPubMedGoogle Scholar
  • 143 Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost 2010; 104 (03) 563-570
    Article in Thieme ConnectPubMedGoogle Scholar
  • 144 Eikelboom JW, Connolly SJ, Bosch J. , et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
    CrossrefPubMedGoogle Scholar
  • 145 Johnston SC, Amarenco P, Albers GW. , et al; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016; 375 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 146 Amarenco P, Albers GW, Denison H. , et al; SOCRATES Steering Committee and Investigators. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol 2017; 16 (04) 301-310
    CrossrefPubMedGoogle Scholar
  • 147 Toyoda K. PRASTRO-1 Study – A Comparison of Prasugrel and Clopidogrel (Standard of Care); 2017 [Abstract]. Available at: http://eso-stroke.org/kategorie-1/esoc-2017-highlights-day-3/ . Accessed November 15, 2017
    PubMed
  • 148 Bonaca MP, Scirica BM, Braunwald E. , et al. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol 2014; 64 (22) 2318-2326
    CrossrefPubMedGoogle Scholar
  • 149 Wang Y, Wang Y, Zhao X. , et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369 (01) 11-19
    CrossrefPubMedGoogle Scholar
  • 150 Li Z, Wang Y, Zhao X. , et al; CHANCE Investigators. Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. J Am Heart Assoc 2016; 5 (03) e003038
    CrossrefPubMedGoogle Scholar
  • 151 De Meyer SF, Schwarz T, Deckmyn H. , et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report. Arterioscler Thromb Vasc Biol 2010; 30 (10) 1949-1951
    CrossrefPubMedGoogle Scholar
  • 152 Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 2009; 10 (11) 1212-1224
    PubMedGoogle Scholar
  • 153 Ablynx announces positive topline results from the phase III hercules study of caplacizumab for the treatment of acquired TTP. 2017
    PubMed
  • 154 Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010; 9 (07) 537-550
    CrossrefPubMedGoogle Scholar
  • 155 Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke 2011; 42 (08) 2149-2153
    CrossrefPubMedGoogle Scholar
  • 156 Jang IK, Gold HK, Ziskind AA. , et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79 (04) 920-928
    CrossrefPubMedGoogle Scholar
  • 157 Tomkins AJ, Schleicher N, Murtha L. , et al. Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke. Exp Transl Stroke Med 2015; 7: 2
    CrossrefPubMedGoogle Scholar
  • 158 Bustamante AL, Boada C, Penalba A. , et al. ADAMTS13 Activity Predicts Response to Thrombolysis in the Acute Stroke Setting. Stroke Suppl 2015
    PubMedGoogle Scholar
  • 159 Borggrefe J, Kottlors J, Mirza M. , et al. Differentiation of clot composition using conventional and dual-energy computed tomography. Clin Neuroradiol 2017
    PubMedGoogle Scholar
  • 160 Mazighi M, Tanasescu R, Ducrocq X. , et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology 2006; 66 (08) 1187-1191
    CrossrefPubMedGoogle Scholar
  • 161 Chimowitz MI, Lynn MJ, Derdeyn CP. , et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365 (11) 993-1003
    CrossrefPubMedGoogle Scholar
  • 162 Kasner SE, Chimowitz MI, Lynn MJ. , et al; Warfarin Aspirin Symptomatic Intracranial Disease Trial Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006; 113 (04) 555-563
    CrossrefPubMedGoogle Scholar
  • 163 Zaidat OO, Fitzsimmons BF, Woodward BK. , et al; VISSIT Trial Investigators. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 2015; 313 (12) 1240-1248
    CrossrefPubMedGoogle Scholar
  • 164 Kim D, Lee SH, Joon Kim B. , et al; for Korean Stroke Registry investigators. Secondary prevention by stroke subtype: a nationwide follow-up study in 46 108 patients after acute ischaemic stroke. Eur Heart J 2013; 34 (35) 2760-2767
    CrossrefPubMedGoogle Scholar
  • 165 Sonneveld MA, Kavousi M, Ikram MA. , et al. Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study. J Thromb Haemost 2016; 14 (11) 2114-2120
    CrossrefPubMedGoogle Scholar
  • 166 Kageyama S, Yamamoto H, Yoshimoto R. Anti-human von willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arterioscler Thromb Vasc Biol 2000; 20 (10) 2303-2308
    CrossrefPubMedGoogle Scholar
  • 167 Zahger D, Fishbein MC, Garfinkel LI. , et al. VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Circulation 1995; 92 (05) 1269-1273
    CrossrefPubMedGoogle Scholar
  • 168 Yamashita A, Asada Y, Sugimura H. , et al. Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity. Arterioscler Thromb Vasc Biol 2003; 23 (06) 1105-1110
    CrossrefPubMedGoogle Scholar
  • 169 Gandhi C, Khan MM, Lentz SR, Chauhan AK. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood 2012; 119 (10) 2385-2391
    CrossrefPubMedGoogle Scholar
  • 170 Jin SY, Tohyama J, Bauer RC, Cao NN, Rader DJ, Zheng XL. Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model. Arterioscler Thromb Vasc Biol 2012; 32 (08) 1817-1823
    CrossrefPubMedGoogle Scholar
  • 171 LaMuraglia GM, Stoner MC, Brewster DC. , et al. Determinants of carotid endarterectomy anatomic durability: effects of serum lipids and lipid-lowering drugs. J Vasc Surg 2005; 41 (05) 762-768
    CrossrefPubMedGoogle Scholar
  • 172 Engelter S, Lyrer P. Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database Syst Rev 2003; (03) CD001458
    PubMedGoogle Scholar
  • 173 Matas M, Domínguez González JM, Montull E. Antiplatelet therapy in endovascular surgery: the RENDOVASC study. Ann Vasc Surg 2013; 27 (02) 168-177
    CrossrefPubMedGoogle Scholar
  • 174 Roubin GS, Yadav S, Iyer SS, Vitek J. Carotid stent-supported angioplasty: a neurovascular intervention to prevent stroke. Am J Cardiol 1996; 78 (3A): 8-12
    PubMedGoogle Scholar
  • 175 Diethrich EB, Ndiaye M, Reid DB. Stenting in the carotid artery: initial experience in 110 patients. J Endovasc Surg 1996; 3 (01) 42-62
    CrossrefPubMedGoogle Scholar
  • 176 Bergeron P, Roux M, Khanoyan P, Douillez V, Bras J, Gay J. Long-term results of carotid stenting are competitive with surgery. J Vasc Surg 2005; 41 (02) 213-221
    CrossrefPubMedGoogle Scholar
  • 177 Kefer JM, Galanti LM, Desmet S, Deneys V, Hanet CE. Time course of release of inflammatory markers after coronary stenting: comparison between bare metal stent and sirolimus-eluting stent. Coron Artery Dis 2005; 16 (08) 505-509
    CrossrefPubMedGoogle Scholar
  • 178 Blann A, Midgley H, Burrows G. , et al. Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplasty. Coron Artery Dis 1993; 4 (10) 905-910
    CrossrefPubMedGoogle Scholar
  • 179 Robless PA, Tegos TJ, Okonko D. , et al. Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets 2002; 13 (04) 231-239
    CrossrefPubMedGoogle Scholar
  • 180 Yang H, Xu JX, Kong XZ. , et al. Relations between plasma von Willebrand factor or endothelin-1 and restenosis following carotid artery stenting. Med Princ Pract 2012; 21 (06) 538-542
    CrossrefPubMedGoogle Scholar
  • 181 Davis JA, Brown AT, Alshafie T. , et al. Saratin (an inhibitor of platelet-collagen interaction) decreases platelet aggregation and homocysteine-mediated postcarotid endarterectomy intimal hyperplasia in a dose-dependent manner. Am J Surg 2004; 188 (06) 778-785
    CrossrefPubMedGoogle Scholar
  • 182 Wang W, Jiang B, Sun H. , et al; NESS-China Investigators. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation 2017; 135 (08) 759-771
    CrossrefPubMedGoogle Scholar
  • 183 Niu JW, Gao S, Cui LY. , et al. Intracranial atherosclerosis in Chinese young adult stroke patients. J Stroke Cerebrovasc Dis 2014; 23 (06) 1519-1523
    CrossrefPubMedGoogle Scholar
  • 184 Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112 (20): 3080-3087
    CrossrefPubMedGoogle Scholar
  • 185 Wieberdink RG, van Schie MC, Koudstaal PJ. , et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 2010; 41 (10) 2151-2156
    CrossrefPubMedGoogle Scholar
  • 186 Wannamethee SG, Whincup PH, Lennon L, Rumley A, Lowe GD. Fibrin D-dimer, tissue-type plasminogen activator, von Willebrand factor, and risk of incident stroke in older men. Stroke 2012; 43 (05) 1206-1211
    CrossrefPubMedGoogle Scholar
  • 187 Jilma-Stohlawetz P, Knöbl P, Gilbert JC, Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost 2012; 108 (02) 284-290
    Article in Thieme ConnectPubMedGoogle Scholar
  • 188 Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knöbl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 105 (03) 545-552
    Article in Thieme ConnectPubMedGoogle Scholar
  • 189 Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 106 (03) 539-547
    PubMedGoogle Scholar
  • 190 Machin SJ, Clarke C, Ikemura O. , et al. A humanized monoclonal antibody against vWF A1 domain inhibits vWF:RiCof activity and platelet adhesion in human volunteers. J Thromb Haemost 2003; 1: Abstract OC328
    PubMedGoogle Scholar
  • 191 Scully M, Knöbl P, Kentouche K. , et al. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood 2017; 130 (19) 2055-2063
    CrossrefPubMedGoogle Scholar
  • 192 Hou Y, Reheman A, Li BX. , et al. Abstract 499: Development of a Novel Antithrombotic Therapy Targeting Platelet GPIbα: Assessment of Anfibatide In Vitro and in Phase I Clinical Trial. Arterioscler Thromb Vasc Biol 2014; 34 (Suppl. 01) A499
    CrossrefPubMedGoogle Scholar